Literature DB >> 17945468

Global and local variations in antimicrobial susceptibilities and resistance development in the major respiratory pathogens.

Celia Alpuche1, Javier Garau, Victor Lim.   

Abstract

Acute respiratory tract infections, such as bacterial pneumonia and acute exacerbations of chronic bronchitis, have been identified by the World Health Organisation as the leading global infectious cause of death. An increasing prevalence of antibiotic resistance has been identified worldwide in the three major bacterial respiratory pathogens -Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae. The selection and spread of resistance is to some degree inevitable and the importance of monitoring its progress has led to the instigation of numerous international, regional and national surveillance programmes. The results from surveillance studies show wide variations in susceptibility rates, both geographically and over time, highlighting the need for local resistance prevalence data in order to guide empirical prescribing and to identify areas in which medical need for new agents is greatest.

Entities:  

Mesh:

Year:  2007        PMID: 17945468     DOI: 10.1016/j.ijantimicag.2007.07.035

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  13 in total

1.  The Impact of Prior Antibiotic Therapy on Outcomes in Children Hospitalized for Community-Acquired Pneumonia.

Authors:  Eran Lavi; Oded Breuer
Journal:  Curr Infect Dis Rep       Date:  2016-01       Impact factor: 3.725

2.  Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae.

Authors:  Kelli Metzler; Karl Drlica; Joseph M Blondeau
Journal:  J Antimicrob Chemother       Date:  2012-11-20       Impact factor: 5.790

3.  Serotype distribution and beta-lactam resistance in Haemophilus influenzae isolated from patients with respiratory infections in Korea.

Authors:  Songmee Bae; Jaehoon Lee; Eunah Kim; Jaehwa Lee; Jaeyon Yu; Yeonho Kang
Journal:  J Microbiol       Date:  2010-03-11       Impact factor: 3.422

Review 4.  Risk Factors for Drug-Resistant Cap in Immunocompetent Patients.

Authors:  Francisco Arancibia; Mauricio Ruiz
Journal:  Curr Infect Dis Rep       Date:  2017-03       Impact factor: 3.725

5.  Antimicrobial resistance in Haemophilus influenzae respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance.

Authors:  Songmee Bae; Jaehoon Lee; Jaehwa Lee; Eunah Kim; Sunhwa Lee; Jaeyon Yu; Yeonho Kang
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

6.  Antibiotic Restriction Might Facilitate the Emergence of Multi-drug Resistance.

Authors:  Uri Obolski; Gideon Y Stein; Lilach Hadany
Journal:  PLoS Comput Biol       Date:  2015-06-25       Impact factor: 4.475

7.  Does the adoption of EUCAST susceptibility breakpoints affect the selection of antimicrobials to treat acute community-acquired respiratory tract infections?

Authors:  Anna Marchese; Susanna Esposito; Ramona Barbieri; Matteo Bassetti; Eugenio Debbia
Journal:  BMC Infect Dis       Date:  2012-08-06       Impact factor: 3.090

8.  Bacterial profile, antibiotic sensitivity and resistance of lower respiratory tract infections in upper egypt.

Authors:  Gamal Agmy; Sherif Mohamed; Yaser Gad; Esam Farghally; Hamdy Mohammedin; Hebba Rashed
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-09-02       Impact factor: 2.576

9.  Antimicrobial resistance trends among community-acquired respiratory tract pathogens in Greece, 2009-2012.

Authors:  Sofia Maraki; Ioannis S Papadakis
Journal:  ScientificWorldJournal       Date:  2014-01-27

10.  Nasopharyngeal carriage and antimicrobial susceptibility of Haemophilus influenzae among children younger than 5 years of age in Beijing, China.

Authors:  Hongbin Zhu; Aihua Wang; Jingjing Tong; Lin Yuan; Wei Gao; Wei Shi; Sangjie Yu; Kaihu Yao; Yonghong Yang
Journal:  BMC Microbiol       Date:  2015-02-04       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.